Acquisition by Gregory Bailey of 16592 shares of Biohaven Pharmaceutical at 38.8 subject to Rule 16b-3
BHVN Stock | USD 46.01 0.37 0.80% |
About 57% of all Biohaven Pharmaceutical's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Biohaven Pharmaceutical Holding suggests that some traders are interested. Biohaven Pharmaceutical's investing sentiment overview a quick insight into current market opportunities from investing in Biohaven Pharmaceutical Holding. Many technical investors use Biohaven Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Biohaven |
Filed transaction by Biohaven Pharmaceutical Holding Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Biohaven Pharmaceutical's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Biohaven Pharmaceutical's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Biohaven Pharmaceutical Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biohaven Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biohaven Pharmaceutical Historical Investor Sentiment
Investor biases related to Biohaven Pharmaceutical's public news can be used to forecast risks associated with an investment in Biohaven. The trend in average sentiment can be used to explain how an investor holding Biohaven can time the market purely based on public headlines and social activities around Biohaven Pharmaceutical Holding. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biohaven Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biohaven Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biohaven Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biohaven Pharmaceutical.
Biohaven Pharmaceutical Fundamental Analysis
We analyze Biohaven Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biohaven Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biohaven Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Biohaven Pharmaceutical is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Biohaven Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biohaven Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Biohaven Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biohaven Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Biohaven Pharmaceutical Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
AGIO | Agios Pharm | 1.24 | ||||
IMNM | Immunome | 0.59 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
APLS | Apellis Pharmaceuticals | 0.62 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
INBX | Inhibrx | 2.37 | ||||
AMLX | Amylyx Pharmaceuticals | 3.48 |
Check out Biohaven Pharmaceutical Hype Analysis, Biohaven Pharmaceutical Correlation and Biohaven Pharmaceutical Performance. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.